In contrast with the increased levels of T cells and CD8+ T cells, which were associated with enhanced TIL infiltration, the reduction of Tregs was observed equally in R and NR cases, indicating  that it may be driven by additional systemic effects of denosumab, rather than by the loss of RANK signaling in the tumor cells, as suggested by the different results seen in RANK−/− tumors. Here, CD8A is linked to neoplasm.